CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.
CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.
05/22/25, 1:34 PM
Location
edmontonIndustry
therapeutics
biotechnology
health care
Investors
Cure Duchenne Ventures
Entos Pharmaceuticals, an Edmonton-based biotech company, received an investment from CureDuchenne Ventures. The company plans to use the funds to develop a therapeutic aimed at delivering full-length dystrophin. This initiative targets the treatment of Duchenne muscular dystrophy (DMD). Entos utilizes its innovative Fusogenix PLV platform for genetic medicine delivery.
Company Info
Location
edmonton, england, united kingdom
Additional Info
Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.